Kornimate/medical-research-clean huggingface dataset:
maternal serum stathmin-1 levels in preeclampsia

Conditions: Preeclampsia

Summary: the goal of this observational study is to investigate maternal serum stathmin-1 levels in pregnancies affected by preeclampsia compared to healthy gestations. the main questions it aims to answer are: 1. what are the maternal serum stathmin-1 levels in pregnancies with preeclampsia? 2. how do stathmin-1 levels differ between preeclampsia with severe features and uncomplicated pregnancies? researchers will compare stathmin-1 levels in pregnancies with preeclampsia and preeclampsia with severe features to those in a control group of healthy pregnancies to assess differences in biomarker levels. participants will undergo blood sample collection at 32-34 weeks of gestation. have their blood samples processed for stathmin-1 level measurement using elisa.


Eligibility criteria:
inclusion criteria: * gestational age: pregnancies between 20 weeks and term (up to 40 weeks). * diagnosis of preeclampsia (pe): new-onset hypertension (systolic bp ≥140 mmhg and/or diastolic bp ≥90 mmhg) after 20 weeks of gestation, with or without proteinuria. * diagnosis of severe preeclampsia: defined by criteria such as severe hypertension (systolic bp ≥160 mmhg or diastolic bp ≥110 mmhg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction. * control group: healthy pregnancies without preeclampsia or other significant maternal or fetal complications. exclusion criteria: * multiple pregnancies: participants carrying more than one fetus. * pregestational diabetes: pre-existing diabetes mellitus diagnosed before pregnancy. * chronic hypertension: pre-existing hypertension diagnosed before pregnancy or before 20 weeks of gestation. * systemic diseases: chronic kidney disease, autoimmune diseases, or other significant systemic illnesses. * fetal anomalies: identified structural or genetic abnormalities in the fetus. * premature rupture of membranes: spontaneous rupture of membranes before the onset of labor at term (37 weeks of gestation) or preterm (before 37 weeks of gestation).

Keywords: stathmin-1 preeclampsia severe preeclampsia trophoblast invasion maternal serum biomarkers
observational retrospective trial on sequential hormonal therapy in patients with prostate cancer

Conditions: Prostate Cancer

Summary: observational retrospective trial on sequential hormonal therapy in patients with prostate cancer


Eligibility criteria:
inclusion criteria: * non metastatic prostate cancer * previous treatment with bicalutamide 150mg * biochemical relapse/progression exclusion criteria: * use of other treatments for prostate cancer

Keywords: second line prostate cancer bicalutamide biochemical relapse/progression in patients with prostate cancer treated with bicalutamide 150mg
association between coronary flow reserve and bh4 levels in high cv risk

Conditions: Hypertension,Essential

Summary: to determine if there is a relationship between coronary flow reserve (cfr) and platelet/plasma bh2 and bh4 levels in patients with high cardiovascular risk .

primary parameter : relationship between coronary flow reserve (cfr) and platelet/plasma bh2 and bh4 levels in patients with hypertension and concomitant cardiovascular risk factors. secondary parameter: levels of cgmp in platelets. 4. study design three parallel groups of patients (n=15 per group): * group 1 with normal coronary flow reserve (cfr ≥2.5) * group 2 with reduced coronary flow reserve (cfr≤2.0) o group 3 control subjects (without a high risk profile according to esc score chart http://www.heartscore.org. ) matched for age (between 40 and 80 years of age) * and gender. 1/3 enrolled patients must be diabetic (type2 diabetes)

Eligibility criteria:
inclusion criteria: * o men and women (females of childbearing potential must be using highly effective contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner) * females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test * between 40 and 80 years of age * documented history of hypertension * smokers/non smokers r * type 2 diabetes r * moderate to severe kidney disease (gfr \>30 and \<60 ml/min/1.73m2 (estimated mdrd) r * hypercholesterolemia r * receiving an optimal standard antihypertensive treatment for at least 6 months, stable for at least 15 days * all other concomitant treatments stabilized at least for the preceding 15 days * able to give written informed consent exclusion criteria: * o females of childbearing potential not using highly effective contraceptive precautions * patients with obstructive (\>50% diameter reduction) cad on the lad (based on invasive angiography or coronary cta) or with evidence of previous myocardial infarction or history of revascularization in the lad territory. * cad on the rca or cx with diameter reduction \> 50% (based on invasive angiography or coronary cta) , either native or revascularized (stent) * patients with infectious disease and/or chronic inflammatory diseases * epicardial coronary arteries spasm * patients with severe valve disease and/or significant left ventricular wall motion abnormalities * patients under treatment with non-selective beta blockers including propranolol, nadolol, pindolol, labetalol, penbutolol, sotalol, carvedilol, and timolol. * contraindications to dipyridamole infusion: asthma, bronchospasm, previous \ 75%. * acute treatment or treatment for acute diseases * patients receiving steroidal anti-inflammatory drugs, dietary supplements of folic acid, or antioxidant vitamins. * any condition that may prevent the pt to give informed consent , enter the study or bias the results. * participating into other studies
interstitial lung disease and obstructive sleep apnea

Conditions: ILD OSA

Summary: clinically, all patients with interstitial lung disease(ild) were observed, and relevant clinical data were collected. bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(rose) was evaluated, combined with the metagenomic next generation sequencing(mngs) results of these patients. to observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. all patients undergo polysomnography (psg) and drug-induced sleep endoscopy(dise). the biological specimens was obtained for molecular biology or other tests.we detected claudin1, claudin2, claudin3, claudin4, and il22 as biomarkers to differentiate the diagnostic efficiency of osa in ild, ild+osa, osa, and ctrl groups, respectively


Eligibility criteria:
inclusion criteria: * over 18 years old and under 80 years old. * clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome. * patient is conscious and capable of signing informed consent. * the patient may wear a polysomnograph. exclusion criteria: * malignant tumors. * severe heart failure. * uremia. * autoimmune diseases. * pulmonary embolism, and end-stage chronic obstructive pulmonary disease. * patients with mental illnesscannot sign informed consent on their own.
apollo™ onyx™ delivery microcatheter post market safety study

Conditions: Arteriovenous Malformations

Summary: the purpose of this study is to evaluate the safety of the apollo™ onyx™ delivery microcatheter used for delivery of the onyx™ liquid embolic system during brain arteriovenous malformation (avm) embolization procedures.

this study is a prospective, single-arm, multicenter, post-market safety evaluation of subjects indicated for embolization of brain avms with the study device. the study device was developed to potentially minimize the side effects of catheter retainment and increased procedural risk associated with alternative methods necessary for removing entrapped catheters. in the event of catheter retainment, using the apollo™ onyx™ delivery microcatheter versus any a standard catheter represents leaving behind a 1.5 - 3.0 cm long detachable tip in the onyx™ onyx™ delivery microcatheter cast versus an average 165 cm long catheter in the vasculature.

Eligibility criteria:
inclusion criteria: * the subject or subject's legally authorized representative has signed and dated an informed consent form. * the subject has a confirmed diagnosis of a brain avm. * the subject is clinically and neurologically stable for a minimum of 48 hours prior to embolization. * the subject has a life expectancy of at least 1 year. * the subject agrees to and is capable of completing all study-required procedures. exclusion criteria: * current participation in another investigational drug or device study that evaluates treatments for brain avms or other cerebrovascular disease. * the subject has a bleeding disorder. * the subject is not a candidate for the use of vasodilators.

Keywords: apollo onyx arteriovenous malformation avm onyx™ liquid embolic system apollo™ onyx™ delivery microcatheter brain diseases
violence in icu: outcomes, lessons, and experiences of icu team (the violent-study)

Conditions: Workplace Stress

Summary: this study aims to investigate the perceptions, experiences, and responses of healthcare professionals working in intensive care units in switzerland concerning patient violence.

workplace violence, as defined by the international labor organization, includes any action, incident, or behavior that assaults, threatens, harms, or injures a person during their work. healthcare workers face the highest risk of workplace violence among all professions. violence can take many forms, including verbal abuse, physical offenses to sexual harassment. while most research focuses on psychiatric and emergency departments, workplace violence in intensive care units (icus) is understudied and often underreported. as a result, little is known about its prevalence and risk factors, leading to a lack of awareness and effective prevention strategies. this study examines the perceptions, experiences, and responses of healthcare professionals in swiss icus. a questionnaire-based survey will assess various aspects, including personal background (such as education and professional role), the frequency and nature of past incidents of workplace violence, responses and measures taken, psychological or professional consequences, current prevention strategies, and suggestions for improving workplace safety. since workplace violence is a common issue, the results of this study could help improve the work environment and safety in icus and other healthcare settings.

Eligibility criteria:
inclusion criteria: * consenting nurses and physicians currently working in swiss intensive care units * nurses and physicians consenting to participate will be included exclusion criteria: * nurses and physicians who do not consent

Keywords: intensive care unit workplace violence
the feasibility and clinical utility of the use of virtual reality for the management of pediatric dental anxiety

Conditions: Children, Only; Dental Anxiety; Behavior

Summary: the use of virtual reality (vr) in pediatric healthcare settings helps to reduce children's pain and anxiety. however, this technology has not been used consistently in pediatric dentistry. consequently, the goal of this study is to investigate the effectiveness of using a virtual reality headset as a distraction technique during dental procedures in children and identify patient and clinician's opinions regarding its use. this study incorporates a single-site, randomized clinical trial design with two paralleled study groups. one group will receive dental treatment following regular standard of care of behavior management while the second group will receive dental treatment using a virtual reality distraction headset. patients in both groups will complete a questionnaire to assess their perception of pain and anxiety before and after the intervention, as well as their satisfaction with the dental treatment. the dentist providing the treatment will also report their observations relating to patient behavior during dental treatment.


Eligibility criteria:
inclusion criteria: * children aged between 6 and 12 years and their accompanying parent/legal-guardian. * children scheduled for one of the following procedures: restorative treatments (amalgam, composite or stainless-steel crowns), pulp therapy and extractions * children that can understand and speak french or english. exclusion criteria: * children diagnosed with a cognitive, auditory, or cognitive impairment preventing them from interacting with the vr game. * children diagnosed with epilepsy or any other condition preventing them from playing the vr game. * children requiring urgent dental care * children requiring dental treatment with conscious sedation (i.e. nitrous oxide inhalation and/or oral sedation with benzodiazepines)
efficacy and safety study of eprotirome in hefh patients who are on optimal standard of care

Conditions: Heterozygous Familial Hypercholesterolaemia

Summary: eprotirome is a liver selective thyroid hormone that can reduce several independent risk factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic tissue. the purpose of this phase iii study is to assess the long-term efficacy and safety of eprotirome in patients with heterozygous familial hypercholesterolaemia who are on optimal standard of care.


Eligibility criteria:
inclusion criteria: * patients with confirmed hefh and 18 years of age at screening * presence of clinical atherosclerotic disease that confers high risk for cad events together with an ldl-c more than 2 mmol/l (more than 80 mg/dl) * presence of risk factors for cvd (other than the hefh diagnosis) together with an ldl-c more than 2.5 mmol/l (more than 100 mg/dl) * on an optimal standard of care, defined as being on a stable dose of statin (rosuvastatin, atorvastatin, or simvastatin) with or without ezetimibe for 8 weeks prior to randomisation exclusion criteria: * significant health problems in recent past including heart failure,cardiac electrophysiologic instability, rheumatoid arthritis, thyroid dysfunction, liver disease, cancer, secondary dyslipidaemia

Keywords: hypercholesterolemia, dyslipidemia, thyroid, safety, heterozygous familial hypercholesterolaemia coronary artery disease
geriatric assessment and nursing telephone intervention in elderly women with ovarian cancer

Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Summary: older woman with ovarian cancer have a worse prognosis compared to younger patients. however, the reason is not known. currently, the standard of care is to evaluate younger and older patients with cancer the same way. however, older patients with cancer often have more complicated issues to manage. for example, older patients often have other medical problems, take more medications, and be dependent on others for help and transportation. too often, the medical team is unaware of these issues which can effect the patients care. the purpose of this study is to apply a set of questions designed specifically for patients with cancer who are older than 65 years of age. these questions are called a geriatric assessment. the investigators want to better understand which older patients with ovarian cancer will be able to tolerate the chemotherapy and surgery and why. this study will also see if a telephone call from a nurse who specializes in caring for older patients will improve patient care. this study will determine how feasible it is to perform geriatric assessments and telephone calls in patients with ovarian cancer.


Eligibility criteria:
inclusion criteria: * patients must be \> or = to age of 65. will receive platinum-based chemotherapy and surgery at mskcc for stage ii-iv ovarian, fallopian tube or peritoneal cancer. * pathologic confirmation or high suspicion based on ca125 level and/or radiologic evidence of ovarian, fallopian tube or peritoneal cancer. * able to understand english. * be able to provide informed consent. exclusion criteria: * enrolled on a phase i trial.

Keywords: geriatric assessment quality of life 11-164 fallopian tubes
the study of serum melatonin rhythm levels in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: one of the main points in the biological trends is, the circadian rhythm and disturbance in this cycle, which cause mood disorders and irregularity in this bio clock, to get depression. the pineal gland with the precise regulation of circadian rhythm of melatonin regulates the brain haemostasis. the abnormal function of this gland gives rise to psychiatric disorders. in the period of youth and early of middle-age cause biochemical changes and disturbance in biorhythm including melatonin secretion. this process can change the peak of melatonin phase. in addition, a decrease in the level of serum melatonin, can change the function of immune system of depressed patients. this function facilitates the process of cancerous cell formation and tumor growth. with respect to the conflicting results and that the positive and negative roles of melatonin in the creation of depression is unknown, the aim of this study was to compare the morning and nocturnal serum melatonin rhythm levels in the patients with major depressive disorder. the second purpose was to measure the morning and nocturnal serum melatonin levels in the depressed and healthy men and women.


Eligibility criteria:
inclusion criteria: 1. age: 22-48 years old 2. gender: male, female 3. who got a depressive score above 20, were included in the depressed group 4. those who obtained a depressive score below 9, were chosen and they were included in the healthy control group. 5. the healthy control group to match to the depressed patients for education, social occasion, occupational and economical situation. 6. the depression disorder was confirmed on the basis of the dsm criteria exclusion criteria: 1. present or past psychiatric 2. physical diagnoses 3. drug consumption 4. use of narcotic substances 5. physical and psychosomatic disorders 6. the stressor 7. malfunction of thyroid gland 8. shift working

Keywords: melatonin periodicity depressive disorder, major serum depression
multicenter study assessing the efficacy and safety of de-126 ophthalmic solution 0.002% compared with timolol maleate ophthalmic solution 0.5% in subjects with primary open angle glaucoma or ocular hypertension

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: reduction of elevated pressure in the eye (intraocular pressure, or 'iop') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss. this study is being conducted to determine how well de-126 ophthalmic solution works (efficacy) in safely lowering iop when dosed as topical eyedrops. this study will evaluate the safety and efficacy of de-126, ophthalmic solution in subjects with primary open angle glaucoma (poag) or ocular hypertension (oht). the iop will be measured at 3 different times throughout the day, over 4 total visits during a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop taking current eye drops to lower iop). safety assessments will be done throughout the study, including ocular signs and symptoms, and vital signs. while the most important time-point to measure iop in this study and evaluate efficacy will be at the final study visit (month 3), iop values will also be evaluated at other visits throughout the 3-month treatment period.


Eligibility criteria:
inclusion criteria: * have been diagnosed of poag or oht in both eyes, or one eye with oag and other with oht * completed the required wait/washout period * qualifying day 1 iop measurement at 3 time-points in both eyes exclusion criteria: * females who are pregnant, nursing, or planning a pregnancy * subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period. * history of ocular surgery specifically intended to lower iop in either eye. laser iridotomy in history is allowed * presence of advanced glaucoma in either eye

Keywords: glaucoma
gon-block in chronic migraine: a randomized, double- blind, placebo-controlled study

Conditions: Chronic Migraine

Summary: infiltration of the greater occipital nerve (gon) with local anaesthetics and corticosteroids is a treatment option for cluster headache. corticosteroids may be helpful in reducing the pain intensity and frequency in chronic migrtaine. this rct is set up to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.

infiltration of the greater occipital nerve (gon) with local anaesthetics and corticosteroids is a treatment option for cluster headache. in general, there is a marked paucity of evidence concerning gon blocks in migraine. corticosteroids may be helpful in reducing the pain intensity and frequency in these patients. this is an rct to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.

Eligibility criteria:
inclusion criteria: * chronic migraine exclusion criteria: * medication overuse headache
pilot study of hypertrophic cardiomyopathy & implantable cardioverter defibrillator assessment: (subcutaneous vs transvenous)

Conditions: Implantable Defibrillator User; Hypertrophic Cardiomyopathy; Implantable Cardioverter Ventricular Lead Dysfunction or Complication; Ventricular Arrythmia

Summary: pilot randomised trial to assess recruitment for a larger trial to compare the efficacy and adverse effects of the subcutaneous and transvenous icd in patients with hypertrophic cardiomyopathy (hcm) and indication for icd therapy, with no requirement for pacing

this study aims to test the feasibility of conducting a trial to investigate the use of subcutaneous implantable defibrillator (sicd) in patients with hypertrophic cardiomyopathy (hcm) and to determine whether sicd produces more complications than conventional, transvenous implantable defibrillator (tv icd). the primary analysis for the main trial is designed to test whether the s-icd is non-inferior to the tv-icd with respect to the primary endpoint of inappropriate shock treatment and complications. for the incidence of the primary endpoint statistical significance and 99% confidence intervals are calculated using cox' proportional hazards model. non-inferiority is considered to be established if the upper boundary of the one-sided 99% confidence interval did not exceed 1.92 (absolute difference \< 12%). participant duration is expected to be 14 months. (12 months follow up post device implant) recruitment duration expected to be 6-10 months.

Eligibility criteria:
inclusion criteria: * hypertrophic cardiomyopathy and a referred for icd therapy with no pacing requirement. exclusion criteria: * patients with sustained ventricular tachycardia less than 170 bpm * patients having an indication for pacing therapy. e.g. sick sinus syndrome. * patients failing appropriate qrs/t-wave sensing with the automated s-icd ecg automated patient screening provided by boston scientific * a minimum of 1 sensing vector passing in supine, standing. * patients with incessant ventricular tachycardia * patients who have had a previous icd implant * patient who receives cardiac contractility modulation therapy or are likely to receive cardiac contractility modulation therapy * patients with a serious known concomitant disease with a life expectancy of less than one year * patients with circumstances that prevent follow-up (no permanent home or address, transient, etc.) * patients who are unable to give informed consent * patients who are not suitable for tv-icd implantation, according to the discretion of the physician, are not screened for enrolment (svc occlusion).

Keywords: transvenous implantable defibrillator subcutaneous implantable defibrillator